Contemporary Evaluation and Clinical Treatment Options for Aortic Regurgitation
- PMID: 37754793
- PMCID: PMC10532324
- DOI: 10.3390/jcdd10090364
Contemporary Evaluation and Clinical Treatment Options for Aortic Regurgitation
Abstract
Aortic regurgitation (AR) is the third most frequent form of valvular disease and has increasing prevalence with age. This will be of increasing clinical importance with the advancing age of populations around the globe. An understanding of the various etiologies and mechanisms leading to AR requires a detailed understanding of the structure of the aortic valve and aortic root. While acute and chronic AR may share a similar etiology, their hemodynamic impact on the left ventricle (LV) and management are very different. Recent studies suggest current guideline recommendations for chronic disease may result in late intervention and suboptimal outcomes. Accurate quantitation of ventricular size and function, as well as grading of the severity of regurgitation, requires a multiparametric and multimodality imaging approach with an understanding of the strengths and weaknesses of each metric. Echocardiography remains the primary imaging modality for diagnosis with supplemental information provided by computed tomography (CT) and cardiac magnetic resonance imaging (CMR). Emerging transcatheter therapies may allow the treatment of patients at high risk for surgery, although novel methods to assess AR severity and its impact on LV size and function may improve the timing and outcomes of surgical intervention.
Keywords: aortic regurgitation; echocardiography; transcatheter aortic valve replacement.
Conflict of interest statement
Dr. Lebehn declares no conflict of interest. Dr. Vahl reports institutional funding to Columbia University Irving Medical Center from Boston Scientific, Edwards Lifesciences, JenaValve, and Medtronic and has received consulting fees from Abbott Vascular, JenaValve, 4C Medical, and Philips. Dr. Kampaktsis declares no conflict of interest. Dr. Hahn reports speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, Medtronic and Philips Healthcare; she has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Edwards Lifesciences, Medtronic and Novartis; she is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored tricuspid valve trials, for which she receives no direct industry compensation.
Figures




References
-
- World Health Organization Ageing. [(accessed on 5 July 2023)]. Available online: https://www.who.int/health-topics/ageing#tab=tab_1.
-
- d’Arcy J.L., Coffey S., Loudon M.A., Kennedy A., Pearson-Stuttard J., Birks J., Frangou E., Farmer A.J., Mant D., Wilson J., et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: The OxVALVE Population Cohort Study. Eur. Heart J. 2016;37:3515–3522. doi: 10.1093/eurheartj/ehw229. - DOI - PMC - PubMed
-
- Gössl M., Stanberry L., Benson G., Steele E., Garberich R., Witt D., Cavalcante J., Sharkey S., Enriquez-Sarano M. Burden of Undiagnosed Valvular Heart Disease in the Elderly in the Community: Heart of New Ulm Valve Study. JACC Cardiovasc. Imaging. 2023;16:1118–1120. doi: 10.1016/j.jcmg.2023.02.009. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials